Precision for Medicine Expands Its Global Footprint for Oncology Development Services
Leadership in Place; Clinical Operations Teams Growing Throughout Europe
Bethesda, MD – July 6th, 2017 – Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent. (more…)
Precisioneffect and Precision for Value Named to MM&M’s Top 100 Healthcare Agencies
Precision is pleased to announce that both precisioneffect and Precision for Value have been named to MM&M magazine’s Top 100 Healthcare Agencies for 2017. The agencies’ perennial inclusion on MM&M’s best list can be directly attributed to strong quantitative capabilities, outstanding creative, and industry-leading client retention. (more…)
Precision Oncology’s Messerschmidt in Managed Healthcare Executive Q&A: Innovative Strategies Help Fight Multiple Myeloma
In Managed Healthcare Executive, Precision Oncology Chief Medical Officer Dr. Gerry Messerschmidt discusses the many recent advances in treating multiple myeloma. (more…)
Precision’s Wilder in PM360: Common Pitfalls to Avoid to Ensure a Successful Product Launch
After spending millions on R&D just to get a product to market—and millions more promoting it—there’s nothing worse than when a launch falls flat. In a just-published panorama on PM360, Precision for Value’s Kelly Wilder identifies several critical mistakes that pharma companies make that can reduce the perceived value of a product in the marketplace. (more…)
Precision’s Schafer in Drug Topics: The Future of Oncology Treatment Is Value Assessment
In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. (more…)